Sustained response seen up to six months after injection<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Oct. 31, 2024 (HealthDay News) — Injected micronized amnion\/chorion bilayer (AC) product significantly reduces time to symptom relief in patients with refractory interstitial cystitis\/bladder pain syndrome (IC\/BPS), according to a study published online Oct. 23 in International Urology & Nephrology<\/em>.<\/p>\n Kyle O\u2019Hollaren, from Wayne State University School of Medicine in Detroit, and colleagues evaluated the therapeutic responses and adverse events of micronized AC in patients with refractory IC\/BPS. The analysis included 15 patients who failed conventional therapy and received 100 mg of reconstituted micronized AC injected intra-detrusor via cystoscopy under general anesthesia using a 23-gauge needle. Twenty 0.5-mL injections were administered into the lateral and posterior bladder walls with outcomes evaluated at six months.<\/p>\n The researchers found that one month after injections, there was significant improvement in IC\/BPS symptom scores in all patients. At six months postinjection, all patients maintained a sustained clinical response. There were no product-related adverse events observed.<\/p>\n “These results suggest a promising clinical benefit of using an amnion\/chorion bilayer product for treating IC\/BPS,” the authors write. “Further research is needed to confirm these findings and assess the long-term durability of this treatment approach. This study represents the first evidence supporting the clinical advantages of an amnion\/chorion bilayer product in managing IC\/BPS.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n